Get started
Work

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study

Year: 2026
Type: article
Source: Blood
DOI: 10.1182/blood.2026033829
Authors: Andre M. Small, Siddharth M. Patel, Robert P. Giugliano, David A. Morrow, Erica L. Goodrich, Bruce Hug, Sanobar Parkar, Shih-Ann Chen, Shaun G. Goodman, Boyoung Joung, Róbert G. Kiss, Wojciech Wojakowski, Jeffrey I. Weitz, Dan Bloomfield, Marc S. Sabatine, Christian T. Ruff
Institutions: Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group, National Yang Ming Chiao Tung University, National Chung Hsing University, China Medical University, Taipei Veterans General Hospital, Taichung Veterans General Hospital, China Medical University Hospital, St. Michael's Hospital, University Health Network, University of Toronto, Unity Health Toronto, Yonsei University, Severance Hospital, Yonsei University Health System, Semmelweis University, Medical University of Silesia, Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, McMaster University
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7162807128
FWCI: 4.573
Cites: 11
Cited by: 1
Related to: